MiRus today announced successful enrollment and treatment of the first patients in the STAR Trial, a prospective, multicenter ...
PuraPly® AM is a patent-protected product that is differentiated among all skin substitutes by combining a native, cross-linked collagen matrix with polyhexamethylene biguanide (PHMB) antimicrobial to ...
1don MSN
Organogenesis stock rockets after diabetic foot ulcer trial posts statistically significant win
Organogenesis Holdings Inc. ORGO shares are up during Tuesday’s premarket session following the company’s announcement of achieving the primary endpoint in a randomized controlled trial evaluating ...
Limited today announced completion of its randomised controlled trial (RCT) evaluating Symphony, with a preliminary study read-out indicating the trial ...
Oxaliplatin-Based Versus Alkylating Agent in Neuroendocrine Tumors According to the O6-Methylguanine-DNA Methyltransferase Status: A Randomized Phase II Study (MGMT-NET) The median time post-HCT was ...
New human research reveals how gut bacteria and creatine may restore brain energy and improve depression. If you have or know ...
Background Adolescence is a critical period for tobacco initiation, and intention to use tobacco strongly predicts uptake. In ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
LifeNet Health, a global leader in regenerative medicine, has received the Best Randomized Controlled Trial Award at the 2026 CAMPs Awards for its Matrion® diabetic foot ulcer study. In this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results